Extended exposure to dietary melatonin reduces tumor number and size in aged male mice

Edward H Sharman1, Kaizhi G Sharman, Stephen C Bondy

  • 1Department of Neurology, University of California, Irvine, CA 92697, USA. esharman@uci.edu

Experimental Gerontology
|September 15, 2010
PubMed

Insights

Dietary melatonin supplementation in male mice significantly reduced tumor incidence and severity in aged animals. This long-term study suggests melatonin

Area of Science:

  • Gerontology
  • Oncology
  • Endocrinology

Background:

  • Aging is associated with increased tumor incidence in mice.
  • Dietary interventions are being explored to mitigate age-related diseases.
  • Melatonin's potential role in aging and disease was previously investigated.

Purpose of the Study:

  • To analyze long-term data on tumor occurrence in melatonin-supplemented mice.
  • To assess the impact of dietary melatonin on tumorigenesis during aging.
  • To evaluate the general relevance of melatonin's anti-tumor effects across mouse strains.

Main Methods:

  • Analysis of tumor data from male mice across multiple experiments over nine years.
  • Comparison of tumor incidence and severity between melatonin-supplemented and control groups.
  • Inclusion of aged mice (≥26 months) and younger controls in the analysis.

Main Results:

  • Melatonin-supplemented mice (≥26 months) exhibited significantly fewer tumors compared to controls.
  • Tumor severity was also lower in aged mice receiving melatonin.
  • Low tumor incidence was observed in younger animals (<25 months) regardless of melatonin supplementation.

Conclusions:

  • Dietary melatonin may reduce tumor burden in aging male mice.
  • The findings suggest a potential role for melatonin in mitigating age-related tumorigenesis.
  • Long-term, multi-strain studies strengthen the generalizability of these observations.